Login
Home
Charts
Search
Watchlist
Products

Park Medi World Ltd

PARKHOSPS·NSE
285.85+0.26%Wed, 23 Sept '26 12:42

Park Medi World Ltd

PARKHOSPS
NSE
285.85
+0.26%
|Wed, 23 Sept '26 12:42
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
12,349Cr
Close
Close Price
285.90
Industry
Industry
Hospitals/Medical Services
PE
Price To Earnings
39.60
PS
Price To Sales
7.03
Revenue
Revenue
1,756Cr
Rev Gr TTM
Revenue Growth TTM
PAT Gr TTM
PAT Growth TTM

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
348354399410410460476
Growth YoY
Revenue Growth YoY%
17.830.119.3
Expenses
ExpensesCr
265265294297311333350
Operating Profit
Operating ProfitCr
838810511399127126
OPM
OPM%
23.825.026.327.524.327.726.5
Other Income
Other IncomeCr
15978988
Interest Expense
Interest ExpenseCr
16161515151410
Depreciation
DepreciationCr
15161515151819
PBT
PBTCr
6766829178103105
Tax
TaxCr
21131613252716
PAT
PATCr
46526679537789
Growth YoY
PAT Growth YoY%
15.846.635.2
NPM
NPM%
13.114.816.419.112.916.718.6
EPS
EPS
1.21.41.72.01.41.82.0
QuarterDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
348354399410410460476
Growth YoY
Revenue Growth YoY%
17.830.119.3
Expenses
ExpensesCr
265265294297311333350
Operating Profit
Operating ProfitCr
838810511399127126
OPM
OPM%
23.825.026.327.524.327.726.5
Other Income
Other IncomeCr
15978988
Interest Expense
Interest ExpenseCr
16161515151410
Depreciation
DepreciationCr
15161515151819
PBT
PBTCr
6766829178103105
Tax
TaxCr
21131613252716
PAT
PATCr
46526679537789
Growth YoY
PAT Growth YoY%
15.846.635.2
NPM
NPM%
13.114.816.419.112.916.718.6
EPS
EPS
1.21.41.72.01.41.82.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7661,0841,2551,2311,3941,6791,756
Growth
Revenue Growth%
41.615.7-1.913.220.5
Expenses
ExpensesCr
4577418649211,0231,2351,291
Operating Profit
Operating ProfitCr
309344390310371444466
OPM
OPM%
40.331.731.125.226.626.526.5
Other Income
Other IncomeCr
3101629323232
Interest Expense
Interest ExpenseCr
24405170615953
Depreciation
DepreciationCr
24354151576267
PBT
PBTCr
265278315218286355378
Tax
TaxCr
68798766708181
PAT
PATCr
197199228152215274297
Growth
PAT Growth%
1.214.4-33.441.727.0
NPM
NPM%
25.718.418.212.315.516.316.9
EPS
EPS
10.113.014.89.95.66.97.2
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7661,0841,2551,2311,3941,6791,756
Growth
Revenue Growth%
41.615.7-1.913.220.5
Expenses
ExpensesCr
4577418649211,0231,2351,291
Operating Profit
Operating ProfitCr
309344390310371444466
OPM
OPM%
40.331.731.125.226.626.526.5
Other Income
Other IncomeCr
3101629323232
Interest Expense
Interest ExpenseCr
24405170615953
Depreciation
DepreciationCr
24354151576267
PBT
PBTCr
265278315218286355378
Tax
TaxCr
68798766708181
PAT
PATCr
197199228152215274297
Growth
PAT Growth%
1.214.4-33.441.727.0
NPM
NPM%
25.718.418.212.315.516.316.9
EPS
EPS
10.113.014.89.95.66.97.2

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
197777777786
Reserves
ReservesCr
2563806108069751,936
Current Liabilities
Current LiabilitiesCr
258353521527557529
Non Current Liabilities
Non Current LiabilitiesCr
212396341450464180
Total Liabilities
Total LiabilitiesCr
8161,2931,5931,9122,1392,813
Current Assets
Current AssetsCr
4317248629871,0341,088
Non Current Assets
Non Current AssetsCr
3855707319251,1051,725
Total Assets
Total AssetsCr
8161,2931,5931,9122,1392,813
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
197777777786
Reserves
ReservesCr
2563806108069751,936
Current Liabilities
Current LiabilitiesCr
258353521527557529
Non Current Liabilities
Non Current LiabilitiesCr
212396341450464180
Total Liabilities
Total LiabilitiesCr
8161,2931,5931,9122,1392,813
Current Assets
Current AssetsCr
4317248629871,0341,088
Non Current Assets
Non Current AssetsCr
3855707319251,1051,725
Total Assets
Total AssetsCr
8161,2931,5931,9122,1392,813

Cash Flow

Consolidated
Standalone
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
223155199367215329
Investing Cash Flow
Investing Cash FlowCr
-233-248-234-76-100-333
Financing Cash Flow
Financing Cash FlowCr
491631-130-89121
Net Cash Flow
Net Cash FlowCr
3970-3416126116
Free Cash Flow
Free Cash FlowCr
866410629970209
CFO To PAT
CFO To PAT%
113.177.987.0241.3100.0120.3
CFO To EBITDA
CFO To EBITDA%
72.245.250.9118.258.174.1
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
223155199367215329
Investing Cash Flow
Investing Cash FlowCr
-233-248-234-76-100-333
Financing Cash Flow
Financing Cash FlowCr
491631-130-89121
Net Cash Flow
Net Cash FlowCr
3970-3416126116
Free Cash Flow
Free Cash FlowCr
866410629970209
CFO To PAT
CFO To PAT%
113.177.987.0241.3100.0120.3
CFO To EBITDA
CFO To EBITDA%
72.245.250.9118.258.174.1

Ratios

Consolidated
Standalone
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8,19212,349
Price To Earnings
Price To Earnings
31.739.6
Price To Sales
Price To Sales
4.97.0
Price To Book
Price To Book
4.16.1
EV To EBITDA
EV To EBITDA
18.326.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
89.870.369.462.359.762.362.3
OPM
OPM%
40.331.731.125.226.626.526.5
NPM
NPM%
25.718.418.212.315.516.316.9
ROCE
ROCE%
50.932.729.018.420.017.317.3
ROE
ROE%
71.743.633.217.220.513.513.5
ROA
ROA%
24.215.414.38.010.19.79.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8,19212,349
Price To Earnings
Price To Earnings
31.739.6
Price To Sales
Price To Sales
4.97.0
Price To Book
Price To Book
4.16.1
EV To EBITDA
EV To EBITDA
18.326.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
89.870.369.462.359.762.362.3
OPM
OPM%
40.331.731.125.226.626.526.5
NPM
NPM%
25.718.418.212.315.516.316.9
ROCE
ROCE%
50.932.729.018.420.017.317.3
ROE
ROE%
71.743.633.217.220.513.513.5
ROA
ROA%
24.215.414.38.010.19.79.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Park Medi World is a doctor-led hospital chain that has stitched together North India’s largest affordable private network by doing something counter-intuitive - chasing government-insured patients that most rivals avoid, and building a collection machine efficient enough to make that pay. Founded by Dr. Ajit Gupta with a single 200-bed hospital in New Delhi in 2005, the company has since built 6 greenfield hospitals and acquired 10 more, becoming the largest private chain in Haryana and the second-largest in North India. The recurring approach is a cluster-based roll-up: buy or build mid-sized hospitals within 50 kilometres of an existing one, plug them into a shared operational backbone, and use the cash those clusters generate to fund the next acquisition or greenfield - a compounding engine that has scaled to 16 hospitals and nearly 4,000 beds without relying heavily on outside capital. # Business segments A single integrated hospital network - one reportable segment, one operating model, one patient funnel - scaled across 14 cities through a cluster strategy that turns individual hospitals into nodes on a shared clinical and operational backbone. ## 1. Multi-specialty hospital services: affordable tertiary care, paid for by the government **The network fills its beds with patients covered by government schemes and self-pay middle-income families, then runs a tight receivables engine that converts slow government payments into predictable cash flow.** - **Government schemes are the demand anchor** - the company is empanelled under ESIC, CGHS, ECHS and Ayushman Bharat, which together provide a steady stream of patients whose bills are ultimately paid by the Central Government; 92% of receivables sit with the government, and the company uploads bills within seven days for clearance within three months. - **In-patient care drives nearly everything** - surgeries, ICU treatments and complex procedures generated 95.6% of patient revenue in FY’26, with the network treating roughly 95,500 in-patients and close to 7.8 lakh out-patients across the year. - **A collection machine, not just a care provider** - government payments come with a built-in gestation period, so the company has designed its entire back-end to handle that lag: debtor days ran at 129 days in FY’26, and the operational model generates enough internal cash to fund technology upgrades and expansion while waiting. - **30 specialties under one roof** - the network covers cardiology, neurology, oncology, orthopaedics, gastroenterology, organ transplants, gene therapy and more, with internal medicine alone contributing 29.5% of specialty revenue. - **Robotic surgery at scale** - the group performed over 150 robotic kidney transplants, roughly 4,700 high-end angioplasties, about 1,200 cardiovascular procedures and approximately 2,600 robot-assisted knee and hip replacements during FY’26, using equipment that includes Da Vinci Robots and the indigenously developed SSI Mantra Robot across three hospitals. ## 2. Hospital network operations: the cluster flywheel **Every new hospital is placed within 50 kilometres of an existing one, so doctors, equipment and second-line managers can be shared - and each cluster becomes denser and cheaper to run as it grows.** - **Clusters, not flagships** - the company deliberately builds regional density rather than scattering hospitals across thin geographies, which creates economies of scale in procurement, doctor sharing and patient referrals. - **Managers are grown inside the system** - second-line management is trained in current hospitals for three to six months before being deployed to a new facility, so the operating playbook replicates with minimal friction. - **Bought and built in equal measure** - of the 16 hospitals, 6 were developed greenfield and 10 were acquired, including purchases under the Insolvency and Bankruptcy Code; acquired hospitals now contribute 70% of beds and 61% of revenue, with an average acquisition cost of ₹3.4 million per bed. - **In-house construction keeps expansion fast and cheap** - the company runs its own construction unit for renovations and new projects, and allocates 70% of beds in less space than typical hospital designs require, which lowers the capital needed for each new bed. - **O&M contracts as a capital-light lever** - for some expansions, the group uses Operations and Maintenance contracts rather than outright ownership, trading lower upfront investment for a faster ramp-up. ## 3. Pharmacy and ancillary services: the tail that follows the patient **Every hospital visit creates a downstream purchase - medicines, diagnostics, consumables - and the network captures that spend inside its own ecosystem.** - **Ancillary revenue rides on patient footfall** - pharmacy and ancillary services form the third revenue stream alongside in-patient and out-patient services, turning the roughly 8.7 lakh patients served annually into a captive retail base. - **A step-down subsidiary built for distribution** - in May 2026, the group incorporated Healplus Medical Services Private Limited as a step-down subsidiary to undertake healthcare and ancillary services, extending the pharmacy logic beyond the hospital gates. # Group structure and partners **A parent company with a growing family of wholly owned and majority-owned subsidiaries - each acquisition typically lands in its own legal entity, preserving asset-level clarity while the centre runs the operating playbook.** - **Promoter-held and tightly controlled** - the founding Gupta family holds approximately 82.9% of the listed parent, Park Medi World Limited, which trades on BSE and NSE under the symbol PARKHOSPS. - **Minority partners in some entities** - the consolidated balance sheet carries non-controlling interests of ₹823 million, indicating that not every subsidiary is fully owned. - **A small non-core divestment** - in June 2026, a wholly owned subsidiary sold its 55% stake in Devina Derma Private Limited for a nominal sum, exiting a dermatology venture that was not material to the hospital network.

Documents — Park Medi World Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/xs2400b5zous642qyh74hcfx.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/yp8x3pnu3212swf5yasqehvl.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/2c2ij0t6zccveq743fgveeye.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/z78u9xajbq5tohur372p7ho5.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/8j1tlb9ury0o9jksjuxx3lfy.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/yu12p9ri64e70c92h5acx2zv.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/l35yckb1tki7gclm2whu2a3s.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/d71kqu9daxffdzdr2s07rlfx.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/nny2x47cdtaj41w0f6kzlz66.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/b3x6ht58xxyatycni43ila5n.pdf

Concall Transcript Summaries — Park Medi World Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3APARKHOSPS/transcript-notes/202606/xs2400b5zous642qyh74hcfx.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3APARKHOSPS/transcript-notes/202603/yp8x3pnu3212swf5yasqehvl.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3APARKHOSPS/transcript-notes/202512/2c2ij0t6zccveq743fgveeye.pdf